MA55404A - Compositions anticancéreuses - Google Patents

Compositions anticancéreuses

Info

Publication number
MA55404A
MA55404A MA055404A MA55404A MA55404A MA 55404 A MA55404 A MA 55404A MA 055404 A MA055404 A MA 055404A MA 55404 A MA55404 A MA 55404A MA 55404 A MA55404 A MA 55404A
Authority
MA
Morocco
Prior art keywords
anticancer compositions
anticancer
compositions
Prior art date
Application number
MA055404A
Other languages
English (en)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MA55404A publication Critical patent/MA55404A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055404A 2014-12-05 2015-12-03 Compositions anticancéreuses MA55404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05

Publications (1)

Publication Number Publication Date
MA55404A true MA55404A (fr) 2022-02-02

Family

ID=52006905

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055404A MA55404A (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses
MA41108A MA41108B1 (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA41108A MA41108B1 (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses

Country Status (31)

Country Link
US (3) US20170360707A1 (fr)
EP (2) EP3226842B1 (fr)
JP (1) JP6767368B2 (fr)
KR (1) KR102348325B1 (fr)
CN (2) CN115837010A (fr)
AR (1) AR102924A1 (fr)
AU (1) AU2015358493B2 (fr)
CA (1) CA2969661C (fr)
CL (1) CL2017001372A1 (fr)
CO (1) CO2017005573A2 (fr)
CR (1) CR20170217A (fr)
CY (1) CY1123856T1 (fr)
DK (1) DK3226842T3 (fr)
EA (1) EA035988B1 (fr)
ES (1) ES2839128T3 (fr)
HR (1) HRP20201902T1 (fr)
HU (1) HUE051888T2 (fr)
IL (1) IL252324B (fr)
LT (1) LT3226842T (fr)
MA (2) MA55404A (fr)
MD (1) MD3226842T2 (fr)
MX (1) MX2017007201A (fr)
NI (1) NI201700069A (fr)
PL (1) PL3226842T3 (fr)
PT (1) PT3226842T (fr)
RS (1) RS61466B1 (fr)
SG (1) SG11201704264UA (fr)
SI (1) SI3226842T1 (fr)
TW (1) TWI683662B (fr)
UA (1) UA121123C2 (fr)
WO (1) WO2016090101A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
EP3226843B1 (fr) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2020144649A1 (fr) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme
CN113365623A (zh) 2019-01-30 2021-09-07 阿拉贡药品公司 用于治疗转移性去势敏感性前列腺癌的抗雄激素
WO2020157704A1 (fr) 2019-01-30 2020-08-06 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
WO2020239478A1 (fr) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques
EP4054572A1 (fr) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Inhibiteurs du récepteur des androgènes pour le traitement du cancer de la prostate non métastatique résistant à la castration chez des sujets présentant une déficience hépatique grave
WO2021245285A1 (fr) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (fr) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Méthodes de traitement du cancer de la prostate
WO2023152611A1 (fr) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide et relugolix pour le traitement du cancer de la prostate
WO2023209555A1 (fr) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate
WO2024189186A1 (fr) 2023-03-16 2024-09-19 Bayer Consumer Care Ag Antagonistes du récepteur des androgènes pour le traitement de patients atteints de récidive biochimique du cancer de la prostate hormonosensible

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324886T1 (de) 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
AU2003292509B2 (en) * 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
ES2593379T3 (es) * 2006-03-27 2016-12-09 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
US9108944B2 (en) * 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2012174436A1 (fr) * 2011-06-15 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulateurs de récepteurs nucléaires et leur utilisation pour le traitement et la prévention d'un cancer
WO2013152342A1 (fr) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Inhibiteur de mtor anticancéreux et combinaison anti-androgène
CA3008345C (fr) 2012-06-07 2019-10-22 Aragon Pharmaceuticals, Inc. Formes cristallines d'un modulateur de recepteur d'androgene
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
CN104661658A (zh) * 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
BR112015015758B1 (pt) * 2013-01-22 2022-01-04 F. Hoffmann-La Roche Ag Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida
WO2014167428A2 (fr) 2013-04-10 2014-10-16 Shilpa Medicare Limited 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CA2940984A1 (fr) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Compositions pharmaceutiques solides d'antagonistes du recepteur des androgenes

Also Published As

Publication number Publication date
CY1123856T1 (el) 2022-05-27
EP3226842B1 (fr) 2020-11-25
BR112017011787A2 (pt) 2017-12-26
CO2017005573A2 (es) 2017-09-29
US20240293321A1 (en) 2024-09-05
HRP20201902T1 (hr) 2021-07-23
MA41108B1 (fr) 2021-03-31
HUE051888T2 (hu) 2021-03-29
RS61466B1 (sr) 2021-03-31
IL252324A0 (en) 2017-07-31
JP6767368B2 (ja) 2020-10-14
TWI683662B (zh) 2020-02-01
EP3842034A1 (fr) 2021-06-30
ES2839128T3 (es) 2021-07-05
PL3226842T3 (pl) 2021-07-12
CL2017001372A1 (es) 2018-01-05
MX2017007201A (es) 2018-01-30
PT3226842T (pt) 2020-12-23
MA41108A (fr) 2016-06-09
EA201791252A1 (ru) 2017-10-31
UA121123C2 (uk) 2020-04-10
CR20170217A (es) 2017-08-30
AR102924A1 (es) 2017-04-05
SI3226842T1 (sl) 2021-04-30
CN106999430A (zh) 2017-08-01
DK3226842T3 (da) 2021-01-25
EA035988B1 (ru) 2020-09-09
EP3226842A1 (fr) 2017-10-11
MD3226842T2 (ro) 2021-03-31
CA2969661C (fr) 2023-04-25
US20170360707A1 (en) 2017-12-21
KR102348325B1 (ko) 2022-01-06
WO2016090101A1 (fr) 2016-06-09
AU2015358493B2 (en) 2021-05-06
US20220151931A1 (en) 2022-05-19
AU2015358493A1 (en) 2017-06-08
SG11201704264UA (en) 2017-06-29
NI201700069A (es) 2017-10-31
CA2969661A1 (fr) 2016-06-09
TW201632187A (zh) 2016-09-16
LT3226842T (lt) 2021-03-25
JP2017536401A (ja) 2017-12-07
IL252324B (en) 2021-10-31
CN115837010A (zh) 2023-03-24
KR20170086657A (ko) 2017-07-26

Similar Documents

Publication Publication Date Title
IL279833A (en) Anti-cancer drugs
DK3361870T3 (da) Fungicidsammensætninger
DK3151672T3 (da) Forbedrede t-celle-sammensætninger
DK3215173T3 (da) Glycopeptidsammensætninger
DK3226842T3 (da) Anticancersammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016023628A2 (pt) composições farmacêuticas.
DK3226843T3 (da) Anticancersammensætninger
DK3040326T3 (da) Haloolefin-baseret sammensætning
BR112017001922A2 (pt) composições fungicidas
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3129007T3 (da) Vaccinesammensætninger
CL2017000639A1 (es) Composición
DK3215127T3 (da) Sammensætninger omfattende cyclosporin
DK3316857T3 (da) Multifasiske sammensætninger
GB201408167D0 (en) Compositions
DK3200827T3 (da) Sammensætninger
DK3337322T3 (da) Fungicidsammensætninger
DK3217964T3 (da) Sammensætning
FR3019552B1 (fr) Composition filmogene
DK3393503T3 (da) Sammensætninger
DK3218439T3 (da) Belægningssammensætninger
DK3441063T3 (da) Flydende thioureylensammensætninger